ILCA | Association Partnerships

Latest from ILCA

Neoadjuvant Nivolumab Plus Electroporation With Curative Intent Safe and Possible in HCC

October 06, 2020

Neoadjuvant immunotherapy with nivolumab plus percutaneous electroporation has demonstrated early signals of promise in the treatment of patients with Barcelona Clinic Liver Cancer class A hepatocellular carcinoma, according to preliminary reports from the phase 2 NIVOLEP trial.

ILCA Data Reignite Interest in AFP as a Biomarker for HCC

October 04, 2020

Although the use of α-fetoprotein has long been established in hepatocellular carcinoma as a biomarker for screening and diagnosis, its role in treatment selection and prognosis following systemic therapy is a moving target.

SIRT Administered With Nivolumab Demonstrates Positive Safety, Tolerability Results in HCC

October 03, 2020

Findings from the NASIR-HCC phase 2 clinical trial demonstrated the safety and tolerability of nivolumab administered with selective internal radiation therapy containing yttrium-90 resin in patients who were ineligible for transarterial chemoembolization.

Advice on Decision Making for Frontline Treatment of HCC

September 21, 2018

Andrew Zhu, MD, PhD, director of Liver Cancer Research and Medicine at Massachusetts General Hospital, shares his advice on making decisions for frontline treatment of patients with hepatocellular carcinoma.

Exploring Immunotherapy Combinations for the Treatment of HCC

September 18, 2018

Novel immunotherapy combinations are currently under investigation for the treatment of patients with hepatocellular carcinoma, with several promising phase III trials incorporating checkpoint inhibitors now underway. Finding successful ways to combine these therapies is among the most significant trends emerging as part of the next wave of discovery in the field, according to experts.